(1) As used in this section, "exome sequence testing" means a genomic technique for sequencing the genome of an individual for diagnostic purposes.
(2) Beginning July 1, 2019, the program shall provide coverage for exome sequence testing:
(a) for a covered individual within the state risk pool who:
(i) is younger than 21 years of age; and
(ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related tests;
(b) performed by a nationally recognized provider with significant experience in exome sequence testing;
(c) that is medically necessary; and
(d) at a rate set by the program.